TriSalus Life Sciences, Inc. cash flow to debt ratio of -52.30% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

TriSalus Life Sciences, Inc.'s free cash flow has increased -54.04% from $-41.19M last year to $-18.93M, signaling increasing performance

TriSalus Life Sciences, Inc.'s debt to equity ratio is 5.26, which means that the company's assets are unhealthy financed, signaling financial risk.

TriSalus Life Sciences, Inc.'s debt has increased relative to shareholder equity from -0.91 last year to 5.26 today, signaling weakened financials

TriSalus Life Sciences, Inc. has negative EBITDA, making leverage ratio unreliable

TriSalus Life Sciences, Inc.'s interest coverage ratio is -5.23, which means that the company struggles to meet interest obligations, signaling financial risk.

TriSalus Life Sciences, Inc.'s profit margin has increased (-44.57%) in the last year from -112.92% to -62.59%, signaling increasing performance

TriSalus Life Sciences, Inc.'s short-term assets of $32.24M exceed its short-term liabilities of $11.50M

TriSalus Life Sciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

TriSalus Life Sciences, Inc.'s return on equity of 273.71%, is higher than 15.00%, indicating good performance

TriSalus Life Sciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

TriSalus Life Sciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

TriSalus Life Sciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

TriSalus Life Sciences, Inc. has negative free cash flow, indicating cash burn

TriSalus Life Sciences, Inc.'s yearly earnings has decreased 18.04% since last year from $-33.23M to $-39.23M, signaling decreasing performance

TriSalus Life Sciences, Inc.'s yearly revenue has increased 53.41% since last year from $29.43M to $45.15M, signaling increasing performance

ROIC -59.22% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

TriSalus Life Sciences, Inc.'s 3-year revenue CAGR of 53.85% is positive, indicating growing revenue over the past 3 years

TriSalus Life Sciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

TriSalus Life Sciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

TriSalus Life Sciences, Inc. has insufficient data to evaluate this check.

TriSalus Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TriSalus Life Sciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

TriSalus Life Sciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

TriSalus Life Sciences, Inc. has insufficient data to evaluate this check.

TriSalus Life Sciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

TriSalus Life Sciences, Inc. has a price-to-book ratio of 49.64x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

TriSalus Life Sciences, Inc. has a price-to-sales ratio of 7.22x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue